| Literature DB >> 35203824 |
Fuhang Song1, Yifei Dong1, Shangzhu Wei2, Xinwan Zhang2, Kai Zhang1, Xiuli Xu2.
Abstract
New polyketide-derived oligophenalenone dimers, bacillisporins K and L (1 and 2) and xanthoradone dimer rugulosin D (3), together with four known compounds, bacillisporin B (4), macrosporusone D (5), rugulosin A and penicillide (6 and 7), were isolated from the marine-derived fungus Talaromyces sp. BTBU20213036. Their structures were determined by detailed analysis of HRESIMS, 1D and 2D NMR data, and the absolute configurations were determined on the basis of calculated and experimental electronic circular dichroism (ECD). The antibacterial and antifungal activities of these compounds were tested against Gram-positive-Staphylococcus aureus, Gram-negative-Escherichia coli, and fungal strain-Candida albicans. These compounds showed potential inhibitory effects against S. aureus with minimum inhibitory concentrations ranging from 0.195 to 100 µg/mL.Entities:
Keywords: Staphylococcus aureus; Talaromyces sp.; antibacterial; marine-derived fungus; polyketide
Year: 2022 PMID: 35203824 PMCID: PMC8868179 DOI: 10.3390/antibiotics11020222
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Chemical structures of 1–7.
1H (500 MHz) and 13C NMR (125 MHz) data of 1, 2 and 5 (in DMSO).
| Position | 1 | 2 | 5 | |||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| 1 | 98.8 | 6.86, s | 99.5 | 6.81, s | 165.1 | |
| 3 | 168.3 | 168.1 | 164.4 | |||
| 3a | 96.4 | 96.2 | 98.4 | |||
| 3b | 130.3 | 130.2 | 134.6 | |||
| 4 | 162.5 | 162.4 | 162.5 | |||
| 5 | 118.4 | 6.96, s | 118.8 | 6.97, s | 120.1 | 7.14, s |
| 6 | 146.7 | 146.6 | 148.1 | |||
| 6a | 118.4 | 118.4 | 118.0 | |||
| 7 | 139.6 | 139.8 | 149.0 | |||
| 8 | 134.3 | 133.8 | 132.5 | |||
| 9 | 152.2 | 152.4 | 160.8 | |||
| 9a | 109.0 | 109.4 | 100.3 | |||
| 1′ | 69.9 | 5.12, d (12.0) | 69.7 | 5.12, d (12.0) | 69.4 | 5.18, d (12.5) |
| 3′ | 167.8 | 167.9 | 167.6 | |||
| 3′a | 103.7 | 103.7 | 104.0 | |||
| 3′b | 147.6 | 147.8 | 147.1 | |||
| 4′ | 163.1 | 163.3 | 163.5 | |||
| 5′ | 119.6 | 6.83, s | 119.7 | 6.83, s | 120.1 | 6.87, s |
| 6′ | 152.2 | 152.4 | 152.5 | |||
| 6′a | 116.6 | 116.7 | 116.6 | |||
| 7′ | 192.5 | 192.5 | 191.2 | |||
| 8′ | 64.9 | 4.83, s | 64.6 | 4.87, d (1.0) | 65.5 | 4.99, s |
| 9′ | 85.1 | 4.77, br s | 85.6 | 4.78, d (5.0) | 85.2 | 4.85, s |
| 9′a | 49.5 | 49.7 | 49.4 | |||
| Me-6 | 24.4 | 2.98, s | 24.6 | 2.99, s | 24.5 | 3.06, s |
| Me-6′ | 23.2 | 2.48, s | 23.2 | 2.47, s | 23.2 | 2.48, s |
| 1″ | 78.6 | 4.12, m | 80.2 | 3.90, m | ||
| 2″ | 68.9 | 3.72, m | 71.3 | 3.61, m | ||
| 3″ | 15.6 | 0.75, d (6.5) | 18.9 | 1.14, d (6.5) | ||
| 4″ | 17.2 | 0.99, d (6.5) | 17.9 | 1.11, d (6.5) | ||
| OH-9′ | 6.24, d (3.0) | 6.31, d (3.0) | ||||
Figure 2Key 1H-1H COSY and HMBC correlations for 1 and 3.
Figure 3Experimental and calculated ECD spectra of 1, 2 and 3.
1H (500 MHz) and 13C NMR (125 MHz) NMR data of 3 and 6 (in DMSO).
| Position | 3 | 6 [ | ||
|---|---|---|---|---|
|
|
| |||
| 1/1′ | 178.1/198.8 | 186.7 | ||
| 2/2′ | 55.7/63.4 | 2.73, d (5.0)/2.90, d (4.5) | 59.0 | 2.77, d (6.0) |
| 3/3′ | 70.2/69.0 | 4.27, dd (5.0, 3.0)/4.56, dd (4.5, 4.0) | 69.2 | 4.38, (dd, 6.0, 2.3) |
| 4/4′ | 48.1/44.0 | 3.46, brs/3.73, brs | 48.4 | 3.36, brs |
| 5/5′ | 53.6/63.9 | 56.3 | ||
| 6/6′ | 120.6/120.1 | 7.46, s/7.41, s | 121.2 | 7.44, d (1.2) |
| 7/7′ | 148.5/148.6 | 148.3 | ||
| 8/8′ | 124.0/123.8 | 7.24, s/7.21, s | 124.7 | 7.18, d (1.2) |
| 9/9′ | 160.9/161.0 | 160.8 | ||
| 10/10′ | 114.3/113.3 | 114.8 | ||
| 11/11′ | 184.8/192.1 | 181.7 | ||
| 12/12′ | 106.8/74.6 | 106.8 | ||
| 13/13′ | 193.0/192.8 | 194.6 | ||
| 14/14′ | 132.3/133.5 | 132.7 | ||
| 15/15′ | 21.6/21.5 | 2.44, s/2.43, s | 22.2 | 2.41, s |
| 9-OH/ | 9-OH′ | 11.71, s/11.04, s | 11.4, s | |
Figure 4Key ROESY correlations of 3.
Antibacterial activity of compounds 1–7 (MIC, µg/mL).
| Number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | Control |
|---|---|---|---|---|---|---|---|---|
|
| >100 | >100 | >100 | >100 | >100 | >100 | >100 | 1 a |
|
| 12.5 | 25 | >100 | 12.5 | 6.25 | 0.195 | 100 | 1 b |
|
| >100 | >100 | >100 | >100 | >100 | >100 | >100 | 1 c |
a Rapamycin, b Vancomycin, c Ciprofloxacin.